CORT Corcept Therapeutics Inc

Price (delayed)

$24.05

Market cap

$2.82B

P/E Ratio

26.14

Dividend/share

N/A

EPS

$0.92

Enterprise value

$2.75B

Sector: Healthcare
Industry: Biotechnology

Highlights

The company's equity rose by 41% YoY and by 7% QoQ
Corcept Therapeutics's debt has decreased by 26% YoY and by 16% QoQ
The P/E is 60% less than the 5-year quarterly average of 65.6 but 35% more than the last 4 quarters average of 19.2
The quick ratio is up by 29% year-on-year but it is down by 6% since the previous quarter

Key stats

What are the main financial stats of CORT
Market
Shares outstanding
117.31M
Market cap
$2.82B
Enterprise value
$2.75B
Valuations
Price to earnings (P/E)
26.14
Price to book (P/B)
5.34
Price to sales (P/S)
7.84
EV/EBIT
21.43
EV/EBITDA
21.07
EV/Sales
7.76
Earnings
Revenue
$353.87M
EBIT
$128.2M
EBITDA
$130.44M
Free cash flow
$150.73M
Per share
EPS
$0.92
Free cash flow per share
$1.31
Book value per share
$4.5
Revenue per share
$3.07
TBVPS
$4.95
Balance sheet
Total assets
$571.73M
Total liabilities
$48.39M
Debt
$2.55M
Equity
$523.34M
Working capital
$431.01M
Liquidity
Debt to equity
0
Current ratio
10.07
Quick ratio
9.83
Net debt/EBITDA
-0.56
Margins
EBITDA margin
36.9%
Gross margin
98.4%
Net margin
30%
Operating margin
36.2%
Efficiency
Return on assets
20.7%
Return on equity
22.6%
Return on invested capital
31.2%
Return on capital employed
24.5%
Return on sales
36.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CORT stock price

How has the Corcept Therapeutics stock price performed over time
Intraday
0.71%
1 week
5.62%
1 month
-4.3%
1 year
89.52%
YTD
-8.07%
QTD
1.09%

Financial performance

How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$353.87M
Gross profit
$348.29M
Operating income
$128.2M
Net income
$106.01M
Gross margin
98.4%
Net margin
30%
The gross profit is up by 16% year-on-year
The revenue rose by 15% year-on-year
Corcept Therapeutics's operating income has increased by 15% YoY but it has decreased by 3.4% from the previous quarter
CORT's net income is up by 13% YoY but it is down by 3.1% QoQ

Growth

What is Corcept Therapeutics's growth rate over time

Valuation

What is Corcept Therapeutics stock price valuation
P/E
26.14
P/B
5.34
P/S
7.84
EV/EBIT
21.43
EV/EBITDA
21.07
EV/Sales
7.76
The P/E is 60% less than the 5-year quarterly average of 65.6 but 35% more than the last 4 quarters average of 19.2
The EPS has grown by 12% year-on-year but it has declined by 3.2% since the previous quarter
The stock's price to book (P/B) is 52% less than its 5-year quarterly average of 11.1 but 20% more than its last 4 quarters average of 4.4
The company's equity rose by 41% YoY and by 7% QoQ
CORT's P/S is 32% above its last 4 quarters average of 5.9 but 7% below its 5-year quarterly average of 8.4
The revenue rose by 15% year-on-year

Efficiency

How efficient is Corcept Therapeutics business performance
The return on equity has declined by 23% year-on-year and by 11% since the previous quarter
CORT's return on assets is down by 22% year-on-year and by 11% since the previous quarter
CORT's ROIC is down by 22% year-on-year and by 10% since the previous quarter
The return on sales has declined by 2.9% since the previous quarter

Dividends

What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CORT.

Financial health

How did Corcept Therapeutics financials performed over time
The company's total assets rose by 39% YoY and by 7% QoQ
The quick ratio is up by 29% year-on-year but it is down by 6% since the previous quarter
Corcept Therapeutics's debt is 100% lower than its equity
CORT's debt to equity has shrunk by 100% QoQ and by 100% YoY
The company's equity rose by 41% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.